Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;26(4):271-277.
doi: 10.11005/jbm.2019.26.4.271. Epub 2019 Nov 30.

Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers

Seong Hee Ahn  1 , So Young Park  2 , Jun-Il Yoo  3 , Youn-Jee Chung  4 , Yun Kyung Jeon  5 , Byung-Ho Yoon  6 , Ha Young Kim  7 , Seung Hun Lee  8 , Jehoon Lee  9 , Seongbin Hong  1
Affiliations

Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers

Seong Hee Ahn et al. J Bone Metab. 2019 Nov.

Abstract

Background: There has been interest in the clinical potential of bone turnover markers (BTMs) as tools both for assessing fracture risk and for monitoring treatment. However, the practical use of BTMs has been limited by their biological variability and difficulties in the interpretation of results. We investigated the current situation of application of BTMs by clinicians in Korea for the management of osteoporosis through a survey asking the patterns of BTMs prescription in clinical practice.

Methods: The survey was conducted online using the "google survey" by the BTM committee authorized by the Korean Society for Bone and Mineral Research.

Results: Total 108 clinicians responded the survey. Most of the respondents prescribed BTMs (80.6%) when they prescribed anti-osteoporotic medications (AOMs). The most frequently prescribed bone resorption and formation markers were serum C-terminal telopeptide of type I collagen (90.7%) and osteocalcin (65.1%), respectively. BTMs were mostly prescribed before starting AOMs (90.8%) and used for the purpose of evaluating treatment response (74.4%). Treatment response and compliance to AOMs were evaluated according to the change of absolute value of BTMs (55.1%). The respondents complained difficulties in the interpretation of BTMs (33.3%), the choice of proper BTMs (17.2%), and the proper sample preparation and handling (13.8%).

Conclusions: In Korea, most of clinicians recognized the benefit of BTMs in the management of osteoporosis. However, there are limitations in the broad use of these markers in clinical practice. Therefore, a clear recommendation for BTM in Korea enhances their use in clinical practice.

Keywords: Biomarkers; Bone remodeling; Osteoporosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Bone turnover markers (BTMs) usually prescribed by 87 Korean clinicians who prescribed BTMs in clinical practice. sOCN, serum osteocalcin; sBSALP, serum bone specific alkaline phosphatase; sP1CP, serum carboxyl-terminal propeptide of type 1 collagen; sP1NP, serum amino-terminal propeptide of type I procollagen; sCTX, serum C-terminal telopeptide of type I collagen; uCTX, urine C-terminal telopeptide of type I collagen; sNTX, serum N-terminal telopeptide of collagen type I; uNTX, urine N-terminal telopeptide of collagen type I; uPYD, urine free and total pyridinoline; uDPD, urine deoxypyridinoline.
Fig. 2
Fig. 2. The time point when 87 Korean clinicians who prescribed bone turnover markers in clinical practice. AOMs, anti-osteoporotic medications.
Fig. 3
Fig. 3. Difficulties in the prescription of bone turnover markers (BTMs) in 87 clinicians who prescribed BTMs in clinical practice.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475. - PubMed
    1. Kang HY, Yang KH, Kim YN, et al. Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health. 2010;10:230. - PMC - PubMed
    1. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467–475. - PubMed
    1. Kanis JA, Melton LJ, 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141. - PubMed
    1. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–1538. - PubMed